Skip to main content
SpringerLink
Log in

Chronic Myelogenous Leukemia

  • Chapter
Allogeneic Stem Cell Transplantation

Part of the book series: Current Clinical Oncology ((CCO))

  • 94 Accesses

Abstract

Chronic myelogenous leukemia (CML) is a malignant hematopoietic stem cell disorder characterized by the Philadelphia chromosome (Ph 1), a balanced translocation of the long arms of chromosomes 9 and 22 (1,2). This translocation results in the juxtaposition of the Bcr and Abl sequences and the creation of a Bcr-Abl fusion protein, a constitutively active cytoplasmic tyrosine kinase. The Bcr-Abl protein phosphorylates several substrates, which activate multiple signal transduction cascades, thus altering cell growth, differentiation, and apoptosis. These activities result in independence from normal growth constraints (3,4).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 74.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Nowell P, Hungerford D. A minute chromosome in human chronic granulocytic leukemia. Science 1960; 132: 1497.

    Google Scholar 

  2. Rowley J. A new consistent chromosomal abnormality in chronic myelogenous leukemia identified by quinacrine fluorescence and Giemsa staining. Nature 1973; 243: 290–293.

    Article  PubMed  CAS  Google Scholar 

  3. Kabarowski J, Witte O. Consequences of bcr-abl expression within the hematopoietic stem cell in chronic myeloid leukemia. Stem Cells 2000; 18: 399–408.

    Article  PubMed  CAS  Google Scholar 

  4. Sawyers C. Chronic myeloid leukemia. N Engl J Med 1999; 340: 1330–1340.

    Article  PubMed  CAS  Google Scholar 

  5. Faded S, Talpaz M, Estrov Z, et al. Chronic myelogenous leukemia: biology and therapy. Ann of Internal Med 1999; 131: 3: 207–219.

    Article  Google Scholar 

  6. Kantarjian HM, Smith TL, O’Brien S, et al. Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-a therapy. Ann Internal Med 1995; 122: 254–261.

    Article  CAS  Google Scholar 

  7. Allan NC, Richards SM, Shepherd P, et al. UK Medical Research Council Randomised, multicentre trial of interferon-a for chronic myeloid leukemia: improved survival irrespective of cytogenetic response. Lancet 1995; 345: 1392–1397.

    Article  PubMed  CAS  Google Scholar 

  8. Kurzrock R, Estov Z, Kantarjian H, et al. Conversion of interferon-induced, long-term cytogenetic remissions in chronic myelogenous leukemia to polymerase chain reaction negativity. J Clinical Oncol 1998; 16: 1526–1531.

    CAS  Google Scholar 

  9. Lee S, Anasetti C, Horowitz M, et al. Initial therapy for chronic myelogenous leukemia: playing the odds. J Clin Oncol 1998; 16: 9: 2897–2903.

    PubMed  CAS  Google Scholar 

  10. Kantarjian H, O’Brien S, Smith T, et al. Treatment of Philadelphia chromosome-positive early chronic phase myelogenous leukemia with daily doses of interferon alpha and low-dose cytosine arabinoside. J Clin Oncol 1999; 17: 284–292.

    PubMed  CAS  Google Scholar 

  11. Guilhot F, Chastang C, Michallet M, et al. Interferon alfa-2b combined with cytarabine versus interferon alone in chronic myelogenous leukemia. N Engl JMed 1997; 337: 223–229.

    Article  CAS  Google Scholar 

  12. Talpaz M, Silver RT, Druker B, et al. The phase II study of STI 571 in adult patients with Philadelphia chromosome positive chronic myeloid leukemia in accelerated phase [abstract]. Blood 2000; 96: 469a.

    Google Scholar 

  13. Kantarjian H, Sawyers C, Hochhaus A, et al. Phase II study of STI571, a tyrosine kinase inhibitor, in patients with resistant or refractory Philadelphia chromosome positive chronic myeloid leukemia (Ph+CML) [abstract]. Blood 2000; 96: 470a

    Google Scholar 

  14. Hochhaus A, Feldman E, Goldman 7M, et al. A phase II study to determine the safety and anti-leukemic effects of STI571 in patients with Philadelphia chromosome positive chronic myeloid leukemia in myeloid blast crisis [abstract]. Blood 2000; 96: 503a.

    Google Scholar 

  15. Druker J, Talpaz M, Resta D, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001; 344: 14: 1031–1037

    Article  PubMed  CAS  Google Scholar 

  16. Appelbaum F, Clift R, Radich J, et al. Bone marrow transplantation for chronic myelogenous leukemia. Semin Oncol 1995; 22: 4: 405–411.

    PubMed  CAS  Google Scholar 

  17. Gale RP, Horowitz M, Ash R, et al. Identical-twin bone marrow transplants for leukemia. Ann Intern Med 1994; 120: 8: 646–652.

    Article  PubMed  CAS  Google Scholar 

  18. Doney K, Buckner CD, Sale GE, et al. Treatment of chronic granulocytic leukemia by chemotherapy, total body irradiation and allogeneic bone marrow transplantation. Exp Hematol 1978: 6: 738–747.

    PubMed  CAS  Google Scholar 

  19. McGlave PB, Arthur DC, Kim TH, et al. Successful allogeneic bone-marrow transplantation for patients in the accelerated phase of chronic granulocytic leukemia. Lancet 1982a; 2: 625–627.

    Article  PubMed  CAS  Google Scholar 

  20. Champlin R, Mitsuyasu R, Elashoff R, et al. Allogeneic bone marrow transplantation for chronic myelogenous leukemia in chronic or accelerated phase. Blood 1982; 60: 1038–1041.

    PubMed  CAS  Google Scholar 

  21. Goldman J, Baughan A. Application of bone marrow transplantation in chronic granulocytic leukemia. Clin Hematol 1983; 12: 3: 739–753.

    Article  CAS  Google Scholar 

  22. Curtis JE, Messner HA. Bone marrow transplantation for leukemia and aplastic anemia: management of ABO incompatibility. Can Med Assoc J 1982; 126: 649–655.

    PubMed  CAS  Google Scholar 

  23. Clift RA, Buckner CD, Thomas ED, et al. Treatment of chronic granulocytic leukemia in chronic phase by allogeneic marrow transplantation. Lancet 1982; 2: 621–623.

    Article  PubMed  CAS  Google Scholar 

  24. Goldman JM, Baughan AS, McCarthy DM, et al. Marrow transplantation for patients in the chronic phase of chronic granulocytic leukemia. Lancet 1982a; 2: 623–625.

    Article  PubMed  CAS  Google Scholar 

  25. Champlin R, Mitsuyasu R, Elashoff R, et al. The role of bone marrow transplantation in the treatment of chronic myelogenous leukemia. In: Gale RP, ed. Recent Advances in Bone Marrow Transplantation. Alan R Liss, New York, 1983.

    Google Scholar 

  26. Thomas ED, Clift RA, Fefer A, et al. Marrow transplantation for the treatment of chronic myelogenous leukemia. Ann Internal Med 1986; 104: 155–163.

    Article  CAS  Google Scholar 

  27. Biggs JC, Szer J, Crilley P, et al. Treatment of chronic myeloid leukemia with allogeneic bone marrow transplantation after preparation with BuCy2. Blood 1992; 80: 5: 1352–1357.

    PubMed  CAS  Google Scholar 

  28. Horowitz MM, Rowlings PA, Passweg JR. Allogeneic bone marrow transplantation for CML: a report from the International Bone Marrow Transplant Registry. Bone Marrow Transplant 1996;17:Suppl 3: s5-s6.

    Google Scholar 

  29. Goldman JM, Szydlo R, Horowitz MM, et al. Choice of pre-transplant treatment and timing of transplants for chronic myelogenous leukemia in chronic phase. Blood 1993; 82: 2235–2238.

    PubMed  CAS  Google Scholar 

  30. Copelan EA, Penza SL, Theil KS, et al. The influence of early transplantation, age, GVHD prevention regimen, and other factors on outcome of allogeneic transplantation for CML following BuCy. Bone Marrow Transplant 2000; 26: 1037–1043.

    Article  PubMed  CAS  Google Scholar 

  31. Beelen DW, Graeven U, Elmaagacli AH, et al. Prolonged administration of interferon-alpha in patients with chronic-phase Philadelphia chromosome-positive chronic myelogenous leukemia prior to allogeneic bone marrow transplantation may adversely affect transplant outcome. Blood 1994; 84: 6: 2026–2043.

    Google Scholar 

  32. Hansen J, Gooley T, Martin P, et al. Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia. N Engl J Med 1998; 338: 962–968.

    Article  PubMed  CAS  Google Scholar 

  33. Hehlmann R, Hochhaus A, Kolb HJ, et al. Interferon-a before allogeneic bone marrow transplantation in chronic myelogenous leukemia does not affect outcome adversely, provided it is discontinued at least 90 days before the procedure. Blood 1999; 94: 11: 3668–3677.

    PubMed  CAS  Google Scholar 

  34. Clift RA, Buckner ED, Thomas WI, et al. Marrow transplantation for chronic myelogenous leukemia: a randomized study comparing cyclophosphamide and total body irradiation with busulfan and cyclophosphamide. Blood 1994; 84: 2036–2043.

    PubMed  CAS  Google Scholar 

  35. Ringden O, Ruutu T, Remberger M, et al. A randomized trial comparing busulfan with total body irradiation as conditioning in allogeneic marrow transplant recipients with leukemia: a report from the Nordic bone marrow transplantation group. Blood 1994; 83: 2723–2730.

    PubMed  CAS  Google Scholar 

  36. Dazzi F, Szydlo RM, Craddock C, et al. Comparison of single-dose and escalating-dose regimens of donor lymphocyte infusion for relapse after allografting for chronic myeloid leukemia. Blood 2000; 95: 1: 67–71.

    PubMed  CAS  Google Scholar 

  37. Guglielmi C, Arcese W, Hermans J, et al. Risk assessment in patients with Ph+ chronic myelogenous leukemia in first relapse after allogeneic stem cell transplant: an EBMT retrospective analysis. Blood 2000; 95: 11: 3328–3334.

    PubMed  CAS  Google Scholar 

  38. Craddock C, Szydlo R, Klein J, et al. Estimating leukemia-free survival after allografting for chronic myeloid leukemia: a new method that takes into account patients who relapse and are restored to complete remission. Blood 2000; 96: 1: 86–90.

    PubMed  CAS  Google Scholar 

  39. Bacigalupo A, Gualandi F, Van Lint MT, et al. Multivariate analysis of risk factors for survival and relapse in chronic granulocytic leukemia following allogeneic marrow transplantation: impact of disease related variables (Sokal score). Bone Marrow Transplant 1993; 12: 443–448.

    PubMed  CAS  Google Scholar 

  40. Gratwohl A, Hermans J, Niederwieser D, et al. Bone marrow transplantation for chronic myeloid leukemia: long term results. Bone Marrow Transplant 1993; 12: 509–516.

    PubMed  CAS  Google Scholar 

  41. Devergie A, Blaise D, Attal M, et al. The French Society of Bone Marrow Graft (SFGM). Allogeneic bone marrow transplantation for chronic myeloid leukemia in first chronic phase: a randomized trial of busulfancytoxan versus cytoxan-total body irradiation as preparative regimen: a report from The French Society of B one Marrow Graft (SFGM). Blood 1995; 85: 2263–2268.

    PubMed  CAS  Google Scholar 

  42. Copelan E, Deeg HJ. Conditioning for allogeneic marrow transplantation in patients with lympho-hematopoietic malignancies without the use of total body irradiation. Blood 1992; 80: 7: 1648–1658.

    PubMed  CAS  Google Scholar 

  43. Slattery JT, Sanders JE, Buckner CD, et al. Graft-rejection and toxicity following bone marrow transplantation in relation to busulfan pharmacokinetics. Bone Marrow Transplant 1995; 16: 31–42.

    PubMed  CAS  Google Scholar 

  44. Grochow LB. The role of therapeutic monitoring in bone marrow transplantation induction regimens. Semin Oncol 1993; 20: 18–25.

    PubMed  CAS  Google Scholar 

  45. Slattery JT, Clift RA, Buckner CD, et al. Marrow transplantation for chronic myeloid leukemia: the influence of plasma busulfan levels on the outcome of transplantation. Blood 1997; 89: 3055–3060.

    PubMed  CAS  Google Scholar 

  46. Copelan EA, Bechtal TP, Avalos BR, et al. Busulfan levels are influenced by prior treatment and are associated with hepatic veno-occlusive disease and early mortality but not with delayed complications following marrow transplantation. Bone Marrow Transplantation 2001; 11: 1121–1124.

    Article  Google Scholar 

  47. Applebaum FR. The future of CML treatment. The American Society of Hematology Conference. San Francisco, CA, December 1, 2000.

    Google Scholar 

  48. Andersson B, Fernandez H, Cagnoni P, et al. IV busulfan, cyclophosphamide (BuCy) and hematopoietic stem cells for non-Hodgkin’s lymphomas (NHL). Proceedings of the American Society for Blood and Marrow Transplantation and the International B one Marrow Transplant Registry/Autologous B lood and Marrow Transplant Registry Tandem BMT Meetings, Keystone Resort, CO, February 28-March 6 [abstract]. 1999; 2: 3.

    Google Scholar 

  49. Vaughan W, Cagnoni P, Fernandez H, et al. Pharmacokinetics of intravenous busulfan in hematopoietic stem cell transplantation (HSCT). Proceedings of the American Society for Blood and Marrow Transplantation and the International Bone Marrow Transplant Registry/Autologous Blood and Marrow Transplant Registry Tandem BMT Meetings, Keystone Resort, CO, February 28-March 6 [abstract]. 1999; 2: 22.

    Google Scholar 

  50. Dinsmore R, Kirkpatrick D, Flomenberg N, et al. Allogeneic bone marrow transplantation for patients with acute nonlymphocytic leukemia. Blood 1984; 63: 649–656.

    PubMed  CAS  Google Scholar 

  51. Geller RB, Saral R, Piantadosi S, et al. Allogeneic bone marrow transplantation after high-dose busulfan and cyclophosphamide in patients with acute nonlymphocytic leukemia. Blood 1989; 73: 2209–2218.

    PubMed  CAS  Google Scholar 

  52. Bolwell B. Is bone marrow transplantation appropriate in older patients ?In: Bolwell B, ed. Current Controversies in Bone Marrow Transplantation. Humana Press, Totowa, New Jersey, 2000.

    Google Scholar 

  53. McGlave P, Arthur D, Hakke R, et al. Therapy of chronic myelogenous leukemia with allogeneic bone marrow transplantation. J Clin Oncol 1987; 5: 1033–1040.

    PubMed  CAS  Google Scholar 

  54. Giralt S, Gaj ewski J, Khouri I, et al. Induction of graft-vs-leukemia as primary treatment of chronic myelogenous leukemia. Blood 1997; 1990 (suppl): 1857a.

    Google Scholar 

  55. Champlin R, Khouri I, Komblau S, et al. Reinventing bone marrow transplantation: nonmyeloablative preparative regimens and induction of graft-vs-malignancy effect. Oncology 1999; 13: 621–628.

    PubMed  CAS  Google Scholar 

  56. Beatty PG, Ash R, Hows JM, et al. The use of unrelated bone marrow donors in the treatment of patients with chronic myelogenous leukemia: experience of four marrow transplant centers. Bone Marrow Transplant 1989; 18: 421–425.

    Google Scholar 

  57. McGlave PB, Beatty P, Ash R, et al. Therapy for chronic myelogenous leukemia with unrelated donor bone marrow transplantation: results in 102 cases. Blood 1990; 75: 1728–1732.

    PubMed  CAS  Google Scholar 

  58. Mackinnon S, Hows JM, Goldman JM, et al. Bone marrow transplantation for chronic myeloid leukemia: the use of histocompatible unrelated volunteer donors. Exp Hematol 1990; 18: 421–425.

    PubMed  CAS  Google Scholar 

  59. McGlave P, Bartsch G, Anasetti C, et al. Unrelated donor marrow transplantation therapy for chronic myelogenous leukemia: initial experience of the National Marrow Donor Program. Blood 1993; 81: 843–850.

    Google Scholar 

  60. Sasazuki T, Juji T, Morishima Y, et al. Effect of matching of class I HLA alleles on clinical outcome after transplantation of hematopoietic stem cells from an unrelated donor. N Engl J Med 1998; 339: 17: 1177–1185.

    Article  PubMed  CAS  Google Scholar 

  61. Petersdorf EW, Gooley TA, Anasetti C, et al. Optimizing outcome after unrelated marrow transplantation by comprehensive matching of HLA class Iand II alleles in the donor and recipient. Blood 1998; 92: 10: 3515–3520.

    PubMed  CAS  Google Scholar 

  62. Fleischauer K, Kernan NA, O’ Reilly RJ, et al. Bone marrow-allograft rejection by T lymphocytes recognizing a single amino acid difference in HLA-B44. N Engl J Med 1990; 323: 1818–1822.

    Article  Google Scholar 

  63. Keever CA, Leong N, Cunnigham I, et al. HLA-B44-directed cytotoxic T cells associated with acute graft-versushost disease following unrelated bone marrow transplantation. Bone Marrow Transplant 1994; 14: 137–145.

    PubMed  CAS  Google Scholar 

  64. Klein JL, Avalos BR, Belt P, et al. Bone marrow engraftment following unrelated donor transplantation utilizing busulfan and cyclophosphamide preparatory chemotherapy. Bone Marrow Transplant 1996; 17: 479–483.

    PubMed  CAS  Google Scholar 

  65. Bertz H, Potthoff K, Mertelsmann R, et al. Busulfan/cyclophosphamide in volunteers unrelated donor (VUD) BMT: excellent feasibility and low incidence of treatment-related toxicity. Bone Marrow Transplant 1997; 19: 1169–1173.

    Article  PubMed  CAS  Google Scholar 

  66. Kroger N, Zabelina T, Kruger W, et al. Comparison of total body irradiation vs busulfan in combination with cyclophosphamide as conditioning for unrelated stem cell transplantation in CML patients. Bone Marrow Transplant 2001; 27: 349–354.

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. Edward Copelan
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Allogeneic Transplant Program, Ireland Cancer Center, University Hospitals of Cleveland, Case Western Reserve University, Cleveland, OH, USA

    Mary J. Laughlin MD

  2. Blood and Marrow Transplant Program, Ireland Cancer Center, University Hospitals of Cleveland, Case Western Reserve University, Cleveland, OH, USA

    Hillard M. Lazarus MD

Rights and permissions

Reprints and permissions

Copyright information

© 2003 Springer Science+Business Media New York

About this chapter

Cite this chapter

Copelan, E. (2003). Chronic Myelogenous Leukemia. In: Laughlin, M.J., Lazarus, H.M. (eds) Allogeneic Stem Cell Transplantation. Current Clinical Oncology. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-333-0_4

Download citation

  • DOI: https://doi.org/10.1007/978-1-59259-333-0_4

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-4757-4481-1

  • Online ISBN: 978-1-59259-333-0

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation